MODIFIED VASOACTIVE INTESTINAL PEPTIDES
The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
1 . A method of treating hypertension, comprising administering to a subject a pharmaceutical composition comprising a Vasoactive Intestinal Peptide Receptor (VPAC) agonist comprising the amino acid sequence of SEQ ID NO:13 having an N-terminal methionine, and an elastin-like polypeptide (ELP) at the C-terminus, and one or more pharmaceutically acceptable excipients, wherein the ELP comprises at least 90 repeat units of VPGXG (SEQ ID NO: 3), where X is independently selected from Val, Ala, and Gly.
2 . The method of claim 1 , wherein the VPAC agonist has increased binding preference for VPAC2 versus VPAC1.
3 . The method of claim 1 , wherein the ELP prolongs the absorption phase from an injection site and extends the circulatory half-life of the peptide agonist.
4 . The method of claim 1 , wherein X is Val, Ala, and Gly in a ratio of 5:2:3.
5 . The method of claim 1 , wherein the pharmaceutical composition is administered parenterally.
6 . The method of claim 5 , wherein the pharmaceutical composition is administered subcutaneously, intramuscularly, or intravenously.
7 . The method of claim 1 , wherein the ELP comprises at least 120 repeat units of VPGXG (SEQ ID NO: 3), where X is independently selected from Val, Ala, and Gly.
8 . The method of claim 7 , wherein X is Val, Ala, and Gly in a ratio of 5:2:3.
9 . The method of claim 1 , wherein the VPAC agonist comprises the amino acid sequence of SEQ ID NO:14.
10 . The method of claim 1 , wherein the hypertension is selected from the group consisting of including pulmonary hypertension, uncontrolled essential hypertension, resistant hypertension, and pulmonary arterial hypertension.
11 . A method of treating hypertension, comprising administering to a subject a pharmaceutical composition comprising a Vasoactive Intestinal Peptide Receptor (VPAC) agonist comprising the amino acid sequence of SEQ ID NO:13 having an N-terminal methionine, and an elastin-like polypeptide (ELP) at the C-terminus, and one or more pharmaceutically acceptable excipients, wherein the ELP comprises at least 90 units of VPGXG (SEQ ID NO:3), where X is Val, Ala, and Gly at a ratio of 5:2:3.
12 . The method of claim 11 , wherein the VPAC agonist has increased binding preference for VPAC2 versus VPAC1.
13 . The method of claim 11 wherein the ELP prolongs the absorption phase from an injection site and extends the circulatory half-life of the peptide agonist.
14 . The method of claim 11 , wherein the elastin-like-polypeptide comprises 120 units of VPGXG (SEQ ID NO: 3).
15 . The method of claim 11 , wherein the pharmaceutical composition is administered parenterally.
16 . The method of claim 15 , wherein the pharmaceutical composition is administered subcutaneously, intramuscularly, or intravenously.
17 . The method of claim 11 , wherein the VPAC agonist comprises the amino acid sequence of SEQ ID NO:14.
18 . The method of claim 11 , wherein the hypertension is selected from the group consisting of including pulmonary hypertension, uncontrolled essential hypertension, resistant hypertension, and pulmonary arterial hypertension.